Kayser Caglar
Research Subjects
Kayser Caglar has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Alper Sonmez
Department of Endocrinology and Metabolism, Ankara Güven Hospital, Ankara, Turkey
2 shared publications Mujdat Yenicesu
Department of Nephrology, Gülhane School of Medicine, Etlik-Ankara, Turkey
2 shared publicationsYusuf Oguz
Department of Nephrology, Gülhane School of Medicine, Etlik-Ankara, Turkey
2 shared publicationsAbdulgaffar Vural
1 shared publication- Abdulgaffar Vural
Department of Nephrology, Gülhane School of Medicine, Etlik, 06018, Ankara, Turkey
1 shared publication - Bengt Lindholm
Renal Medicine, Karolinska Institutet, M99 Karolinska University Hospital Huddinge, Stockholm, Sweden
1 shared publication
Latest Publications
- 1 June 2009
- Published by Elsevier in Kidney International
- Vol. 75 (12) , 1316-1321
Hemoglobin is inversely related to flow-mediated dilatation in chronic kidney disease
- 1 June 2009
- Published by Elsevier in Kidney International
- Vol. 75 (12) , 1316-1321
Hemoglobin is inversely related to flow-mediated dilatation in chronic kidney disease
- 11 March 2008
- Published by S. Karger AG in Nephron Clinical Practice
- Vol. 108 (3) , c233-c240
Serum Fetuin-A Concentration and Endothelial Dysfunction in Chronic Kidney Disease
Background: Defective endothelial function, an initial step in the development of atherosclerotic plaque, is prevalent in moderate to advanced chronic kidney disease (CKD). In this study, the investigators hypothesized that fetuin-A, a calcification inhibitor, is a novel risk factor for the development of endothelial dysfunction in patients. Methods: 198 nondiabetic patients with a mean age of 44.0 ± 12.4 years and with different stages of CKD were studied. In addition to a detailed metabolic panel, flow-mediated dilatation assessed by high-resolution brachial ultrasonography was performed to determine endothelial dysfunction. Carotid intima-media thickness was also estimated by ultrasonography. Serum fetuin-A concentrations were determined by using a human ELISA method. Results: Endothelial dysfunction was observed in all stages (1–5) of CKD and worsened in parallel to the reduction in estimated glomerular filtration rate. Serum fetuin-A concentrations were also found to be decreased in all but stage 1 CKD. On multiple regression analysis, endothelial dysfunction was independently associated with fetuin-A (β = 0.745, p < 0.001) and intact parathyroid hormone concentrations (β = –0.216, p < 0.001). Conclusion: These data in a selected cohort of CKD patients indicate that fetuin-A may be one of the contributing factors for the development of endothelial dysfunction in CKD patients.
- 11 March 2008
- Published by S. Karger AG in Nephron Clinical Practice
- Vol. 108 (3) , c233-c240
Serum Fetuin-A Concentration and Endothelial Dysfunction in Chronic Kidney Disease
Background: Defective endothelial function, an initial step in the development of atherosclerotic plaque, is prevalent in moderate to advanced chronic kidney disease (CKD). In this study, the investigators hypothesized that fetuin-A, a calcification inhibitor, is a novel risk factor for the development of endothelial dysfunction in patients. Methods: 198 nondiabetic patients with a mean age of 44.0 ± 12.4 years and with different stages of CKD were studied. In addition to a detailed metabolic panel, flow-mediated dilatation assessed by high-resolution brachial ultrasonography was performed to determine endothelial dysfunction. Carotid intima-media thickness was also estimated by ultrasonography. Serum fetuin-A concentrations were determined by using a human ELISA method. Results: Endothelial dysfunction was observed in all stages (1–5) of CKD and worsened in parallel to the reduction in estimated glomerular filtration rate. Serum fetuin-A concentrations were also found to be decreased in all but stage 1 CKD. On multiple regression analysis, endothelial dysfunction was independently associated with fetuin-A (β = 0.745, p < 0.001) and intact parathyroid hormone concentrations (β = –0.216, p < 0.001). Conclusion: These data in a selected cohort of CKD patients indicate that fetuin-A may be one of the contributing factors for the development of endothelial dysfunction in CKD patients.